The immunogenic radiation and new players in immunotherapy and targeted therapy for head and neck cancer

S Sharon, N Daher-Ghanem, D Zaid, MJ Gough… - Frontiers in Oral …, 2023 - frontiersin.org
Although treatment modalities for head and neck cancer have evolved considerably over the
past decades, survival rates have plateaued. The treatment options remained limited to …

Localized Drug Delivery Systems: An Update on Treatment Options for Head and Neck Squamous Cell Carcinomas

A Hariharan, SD Tran - Pharmaceutics, 2023 - mdpi.com
Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers in
the world, with surgery, radiotherapy, chemotherapy, and immunotherapy being the primary …

[HTML][HTML] Induction of immune responses and phosphatidylserine exposure by TLR9 activation results in a cooperative antitumor effect with a phosphatidylserine …

JC Tseng, JX Yang, CY Lee, CF Lo, YL Liu… - … journal of biological …, 2023 - ncbi.nlm.nih.gov
Head and neck cancer is a major cancer type, with high motility rates that reduce the quality
of life of patients. Herein, we investigated the effectiveness and mechanism of a combination …

[HTML][HTML] A senescence-related lncRNA signature predicts prognosis and reflects immune landscape in HNSCC

L Chen, J Lin, Y Wen, B Lan, J Xiong, Y Fu, Y Chen… - Oral Oncology, 2024 - Elsevier
Abstract Objective Long noncoding RNAs (lncRNAs) regulate cancer cell senescence in
many cancers. However, their specific involvement in head and neck squamous cell …

Accelerated Aging and Microsatellite Instability in Recessive Dystrophic Epidermolysis Bullosa–Associated Cutaneous Squamous Cell Carcinoma

CAA Lee, S Wu, YT Chow, E Kofman, V Williams… - Journal of Investigative …, 2024 - Elsevier
Recessive dystrophic epidermolysis bullosa (RDEB) is a severely debilitating disorder
caused by pathogenic variants in COL7A1 and is characterized by extreme skin fragility …

Overcoming Resistance to Standard-of-Care Therapies for Head and Neck Squamous Cell Carcinomas

C Gauss, LD Stone, M Ghafouri, D Quan, J Johnson… - Cells, 2024 - mdpi.com
Although there have been some advances during in recent decades, the treatment of head
and neck squamous cell carcinoma (HNSCC) remains challenging. Resistance is a major …

[HTML][HTML] Developing and validating the model of tumor-infiltrating immune cell to predict survival in patients receiving radiation therapy for head and neck squamous …

T Xu, M Xu, Y Xu, X Cai, MJ Brenner… - Translational Cancer …, 2024 - ncbi.nlm.nih.gov
Background Radiotherapy (RT) is a mainstay of head and neck squamous cell carcinoma
(HNSCC) treatment. Due to the influence of RT on tumor cells and immune/stromal cells in …

Pembrolizumab as an immunotherapy drug in the treatment of a patient with recurrent (unresectable) cancer of the lower lip

LY Markulan, LM Makarevych - General Surgery, 2022 - generalsurgery.com.ua
Advances in immunotherapy have changed approaches to the treatment of recurrent and/or
metastatic head and neck squamous cell carcinoma (R/M HNSCC). The US Food and Drug …

[PDF][PDF] Localized Drug Delivery Systems: An Update on Treatment Options for Head and Neck Squamous Cell Carcinomas. Pharmaceutics 2023, 15, 1844

A Hariharan, SD Tran - 2023 - academia.edu
Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers in
the world, with surgery, radiotherapy, chemotherapy, and immunotherapy being the primary …